🚀 VC round data is live in beta, check it out!
Disc Medicine Valuation Multiples
Discover revenue and EBITDA valuation multiples for Disc Medicine and similar public comparables like Nanjing King-Friend, Immunome, Jafron Biomedical, Lotus Pharmaceutical and more.
Disc Medicine Overview
About Disc Medicine
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company’s preclinical programs include DISC-0998.
Founded
2015
HQ
Employees
84
Website
Sectors
Financials (LTM)
EV
$2B
Disc Medicine Financials
Disc Medicine reported last 12-month revenue of — and negative EBITDA of ($246M).
In the same LTM period, Disc Medicine generated ($376K) in gross profit, ($246M) in EBITDA losses, and had net loss of ($227M).
Revenue (LTM)
Disc Medicine P&L
In the most recent fiscal year, Disc Medicine reported revenue of — and EBITDA of ($208M).
Disc Medicine expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Gross Profit | ($376K) | XXX | — | XXX | XXX | XXX |
| EBITDA | ($246M) | XXX | ($208M) | XXX | XXX | XXX |
| Net Profit | ($227M) | XXX | ($212M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Disc Medicine Stock Performance
Disc Medicine has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Disc Medicine's stock price is $60.31.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | 0.0% | XXX | XXX | XXX | $-5.56 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialDisc Medicine Valuation Multiples
Disc Medicine trades at (6.3x) EV/EBITDA.
EV / Revenue (LTM)
Disc Medicine Financial Valuation Multiples
As of March 23, 2026, Disc Medicine has market cap of $2B and EV of $2B.
Equity research analysts estimate Disc Medicine's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Disc Medicine has a P/E ratio of (10.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/EBITDA | (6.3x) | XXX | (7.4x) | XXX | XXX | XXX |
| EV/EBIT | (6.2x) | XXX | (6.5x) | XXX | XXX | XXX |
| EV/Gross Profit | (4095.9x) | XXX | — | XXX | XXX | XXX |
| P/E | (10.1x) | XXX | (10.8x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (8.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Disc Medicine Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Disc Medicine Margins & Growth Rates
Disc Medicine's revenue in the last fiscal year grew by —.
Disc Medicine's revenue per employee in the last FY averaged $0.0M.
Disc Medicine Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | 19% | XXX | 35% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Disc Medicine Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Nanjing King-Friend | XXX | XXX | XXX | XXX | XXX | XXX |
| Immunome | XXX | XXX | XXX | XXX | XXX | XXX |
| Jafron Biomedical | XXX | XXX | XXX | XXX | XXX | XXX |
| Lotus Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Mineralys Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Disc Medicine M&A Activity
Disc Medicine acquired XXX companies to date.
Last acquisition by Disc Medicine was on XXXXXXXX, XXXXX. Disc Medicine acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Disc Medicine
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialDisc Medicine Investment Activity
Disc Medicine invested in XXX companies to date.
Disc Medicine made its latest investment on XXXXXXXX, XXXXX. Disc Medicine invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Disc Medicine
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Disc Medicine
| When was Disc Medicine founded? | Disc Medicine was founded in 2015. |
| Where is Disc Medicine headquartered? | Disc Medicine is headquartered in United States. |
| How many employees does Disc Medicine have? | As of today, Disc Medicine has over 84 employees. |
| Who is the CEO of Disc Medicine? | Disc Medicine's CEO is John D. Quisel. |
| Is Disc Medicine publicly listed? | Yes, Disc Medicine is a public company listed on Nasdaq. |
| What is the stock symbol of Disc Medicine? | Disc Medicine trades under IRON ticker. |
| When did Disc Medicine go public? | Disc Medicine went public in 2021. |
| Who are competitors of Disc Medicine? | Disc Medicine main competitors are Nanjing King-Friend, Immunome, Jafron Biomedical, Lotus Pharmaceutical. |
| What is the current market cap of Disc Medicine? | Disc Medicine's current market cap is $2B. |
| Is Disc Medicine profitable? | No, Disc Medicine is not profitable. |
| What is the current EBITDA of Disc Medicine? | Disc Medicine has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Disc Medicine? | Current EBITDA multiple of Disc Medicine is (6.3x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.